Article Text

Download PDFPDF

313 Enhancing anti-cancer activity of therapeutic T-cells with a synapse-stabilizing receptor
  1. Chiou-Tsun Tsai,
  2. Norihiro Watanabe and
  3. Maksim Mamonkin
  1. Baylor College of Medicine, Houston, TX, USA


Background CAR T-cells show remarkable efficacy against B-cell malignancies with uniformly high expression of target antigens. In contrast, tumors with low/heterogenous antigen expression often evade CAR-T cytotoxicity and necessitate multi-antigen targeting which often broadens off-tumor toxicity. We hypothesized cytotoxicity of CAR T-cells targeting low/heterogeneous antigens can be selectively augmented with an additional non-cytotoxic receptor specific to another abundantly expressed tumor antigen. This synapse-stabilizing receptor (SSR) would facilitate formation of a cytotoxic immune synapse and CAR-mediated killing of tumor cells without directly eliciting T-cell degranulation therefore limiting additional toxicity against healthy tissues.

Methods To model suboptimal antigen targeting, we used CLL1-specific CAR and survivin (Sur)-specific TCR which produce limited cytotoxicity against acute myeloid leukemia (AML) cells with low/intermediate antigen expression. Using gammaretroviral transduction, we armed these T-cells with an SSR targeting CD38, an antigen highly expressed in leukemia but also in critical hematopoietic progenitors. SSR-armed CAR- and TCR-T cells have been evaluated in preclinical models of human AML and in coculture assays with normal CD38+ mature and progenitor cells.

Results SSR arming significantly increased cytotoxicity of CLL-1.CAR T-cells against antigen-low AML line MOLM-13. Integrating into the SSR a modified signaling endodomain of LAT (modLAT177) further enhanced secretion of IFN-γ, IL2 and TNF-α as well as T-cell degranulation (measured by CD107a/granzymeB staining) in both CD4+ (P=0.0066). and CD8+ T-cells(P=0.0189). Similar results were observed with SurTCR where SSR arming enabled killing THP-1 AML cells that were otherwise resistant to Sur.TCR cytotoxicity. SSR expression effectively masked CD38 on T-cell surface and protected them from daratumumab (CD38 mAb) in vitro thus enabling combinatorial immunotherapeutic approaches. In vivo, SSR-armed CLL-1.CAR T-cells mounted greater systemic expansion and produced a >30-fold reduction of circulating leukemic blasts in a mouse xenograft model of AML significantly extending animal survival compared to a group receiving unarmed CLL-1 CART (P=0.0039). Because SSR design precluded heterodimerization with the CAR, we observed no CD38-directed toxicity of SSR-armed CLL-1.CAR T-cells against normal CLL-1-negative CD38-positive mature (NK-cells) and hematopoietic progenitor cells in cord-blood CFU assays.

Conclusions Arming engineered T-cells with a non-cytotoxic SSR with integrated modLAT177 signaling augmented their selective tumor cytotoxicity and expansion without broadening off-tumor cytotoxicity against normal tissues. This approach can be utilized to enhance immunotherapy against tumors with suboptimal levels of antigen expression while preserving specificity of targeting through a quasi-Boolean ‘AND’ gate.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.